首页> 外文期刊>International journal of clinical pharmacology and therapeutics >Comparative bioequivalence study of two isotretinoin soft gel capsule formulations in healthy male volunteers.
【24h】

Comparative bioequivalence study of two isotretinoin soft gel capsule formulations in healthy male volunteers.

机译:两种异维A酸软胶囊制剂在健康男性志愿者中的生物等效性比较研究。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To assess the bioequivalence of 2 oral isotretinoin (20 mg) soft gel capsule formulations. The reference preparation was Roaccutan/Roche while the test preparation was A-Cnotren/Pharmaten, Athens, Greece. SUBJECTS, MATERIAL AND METHODS: The study was an open, randomized, 2-period, 2-sequence, 2-treatment crossover, involving 38 healthy male volunteer subjects. All volunteers completed the study. Isotretinoin plasma concentrations were measured by a fully validated HPLC method. Special care was taken through the collection and analysis of the samples due to instability of isotretinoin to light and temperature. Pharmacokinetic parameters used to assess bioequivalence were AUC(0-last), AUC(0-infinity) for the extent of absorption and Cmax and Tmax for the rate of absorption. Statistical evaluation of Cmax, AUC(0-last), AUC(0-infinity) was done after semi-logarithmic transformation by 2-way analysis of variance (ANOVA). Tmax values were tested using the distribution-free Hodges-Lehman interval. RESULTS: The parametric 90% confidence intervals for ratio T/R ranged from 95.20-103.20% (point estimate 99.10%) for AUC(0-last), 94.57-102.30% (point estimate 98.36%) for AUC(0-infinity) and 94.81-102.90% (point estimate 98.77%) for Cmax, respectively. Based on the results of Tmax, k(el) and t(1/2), too, there were no statistically significant differences. CONCLUSION: As a result, the 2 isotretinoin preparations in accordance with the European Union bioequivalence requirements, are equivalent with respect to rate and extent of absorption.
机译:目的:评估2种口服异维A酸(20毫克)软胶囊的生物等效性。参考制剂是Roaccutan / Roche,而测试制剂是A-Cnotren / Pharmaten,希腊雅典。受试者,材料和方法:该研究是一项开放,随机,2期,2序列,2治疗的交叉试验,涉及38位健康的男性志愿者受试者。所有志愿者完成了研究。异维A酸血浆浓度通过完全验证的HPLC方法测量。由于异维A酸对光和温度的不稳定性,因此在收集和分析样品时要格外小心。用于评估生物等效性的药代动力学参数是AUC(0-last),AUC(0-infinity)的吸收程度和Cmax和Tmax的吸收率。半对数转换后,通过2方差分析(ANOVA)对Cmax,AUC(0-last),AUC(0-infinity)进行统计评估。使用无分布Hodges-Lehman间隔测试Tmax值。结果:T / R的参数90%置信区间介于AUC(0-last)的95.20-103.20%(点估计99.10%),AUC(0-infinity)的94.57-102.30%(点估计98.36%) Cmax分别为94.81-102.90%(点估计为98.77%)。根据Tmax,k(el)和t(1/2)的结果,也没有统计学上的显着差异。结论:根据欧盟生物等效性要求,这两种异维A酸制剂在吸收速率和吸收程度方面是等效的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号